Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy

Interleukin-33 (IL-33) and its “decoy” receptor soluble ST2 (sST2) are involved in the development of chronic inflammation and cancer. We explored IL-33 and sST2 as a potential prognostic marker in patients with metastatic and locally advanced pancreatic ductal adenocarcinoma (PDAC). IL-33 and sST2...

Descripción completa

Detalles Bibliográficos
Autores principales: Kieler, Markus, Unseld, Matthias, Wojta, Johann, Kaider, Alexandra, Bianconi, Daniela, Demyanets, Svitlana, Prager, Gerald W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244890/
https://www.ncbi.nlm.nih.gov/pubmed/30426271
http://dx.doi.org/10.1007/s12032-018-1223-3
_version_ 1783372136683929600
author Kieler, Markus
Unseld, Matthias
Wojta, Johann
Kaider, Alexandra
Bianconi, Daniela
Demyanets, Svitlana
Prager, Gerald W.
author_facet Kieler, Markus
Unseld, Matthias
Wojta, Johann
Kaider, Alexandra
Bianconi, Daniela
Demyanets, Svitlana
Prager, Gerald W.
author_sort Kieler, Markus
collection PubMed
description Interleukin-33 (IL-33) and its “decoy” receptor soluble ST2 (sST2) are involved in the development of chronic inflammation and cancer. We explored IL-33 and sST2 as a potential prognostic marker in patients with metastatic and locally advanced pancreatic ductal adenocarcinoma (PDAC). IL-33 and sST2 plasma levels were assessed in 20 patients with advanced PDAC before start of systemic chemotherapy and were analyzed in relation to clinical outcome. Kaplan Meier and multivariable Cox proportional hazards model analysis revealed a significant association between sST2 plasma levels and survival (HR 2.10, 95% CI 1.33–3.41, p = 0.002) and link high sST2 plasma levels to inferior survival in patients with advanced PDAC undergoing chemotherapy.
format Online
Article
Text
id pubmed-6244890
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-62448902018-12-04 Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy Kieler, Markus Unseld, Matthias Wojta, Johann Kaider, Alexandra Bianconi, Daniela Demyanets, Svitlana Prager, Gerald W. Med Oncol Original Paper Interleukin-33 (IL-33) and its “decoy” receptor soluble ST2 (sST2) are involved in the development of chronic inflammation and cancer. We explored IL-33 and sST2 as a potential prognostic marker in patients with metastatic and locally advanced pancreatic ductal adenocarcinoma (PDAC). IL-33 and sST2 plasma levels were assessed in 20 patients with advanced PDAC before start of systemic chemotherapy and were analyzed in relation to clinical outcome. Kaplan Meier and multivariable Cox proportional hazards model analysis revealed a significant association between sST2 plasma levels and survival (HR 2.10, 95% CI 1.33–3.41, p = 0.002) and link high sST2 plasma levels to inferior survival in patients with advanced PDAC undergoing chemotherapy. Springer US 2018-11-13 2019 /pmc/articles/PMC6244890/ /pubmed/30426271 http://dx.doi.org/10.1007/s12032-018-1223-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
Kieler, Markus
Unseld, Matthias
Wojta, Johann
Kaider, Alexandra
Bianconi, Daniela
Demyanets, Svitlana
Prager, Gerald W.
Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
title Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
title_full Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
title_fullStr Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
title_full_unstemmed Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
title_short Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
title_sort plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244890/
https://www.ncbi.nlm.nih.gov/pubmed/30426271
http://dx.doi.org/10.1007/s12032-018-1223-3
work_keys_str_mv AT kielermarkus plasmalevelsofinterleukin33andsolublesuppressionoftumorigenicity2inpatientswithadvancedpancreaticductaladenocarcinomaundergoingsystemicchemotherapy
AT unseldmatthias plasmalevelsofinterleukin33andsolublesuppressionoftumorigenicity2inpatientswithadvancedpancreaticductaladenocarcinomaundergoingsystemicchemotherapy
AT wojtajohann plasmalevelsofinterleukin33andsolublesuppressionoftumorigenicity2inpatientswithadvancedpancreaticductaladenocarcinomaundergoingsystemicchemotherapy
AT kaideralexandra plasmalevelsofinterleukin33andsolublesuppressionoftumorigenicity2inpatientswithadvancedpancreaticductaladenocarcinomaundergoingsystemicchemotherapy
AT bianconidaniela plasmalevelsofinterleukin33andsolublesuppressionoftumorigenicity2inpatientswithadvancedpancreaticductaladenocarcinomaundergoingsystemicchemotherapy
AT demyanetssvitlana plasmalevelsofinterleukin33andsolublesuppressionoftumorigenicity2inpatientswithadvancedpancreaticductaladenocarcinomaundergoingsystemicchemotherapy
AT pragergeraldw plasmalevelsofinterleukin33andsolublesuppressionoftumorigenicity2inpatientswithadvancedpancreaticductaladenocarcinomaundergoingsystemicchemotherapy

Ejemplares similares